Drugs / Allogenic mesenchymal stem cells from adipose tissue
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01678534 | Sep 2014 → Dec 2017 | ischemic stroke | Instituto de Investigación Hospital Universitario La Paz | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic mesenchymal stem cells from adipose tissue | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01678534 ↗ |
| Known as | MSCs | “Intravenous administration of allogeneic mesenchymal stem cells (MSCs) from adipose tissue in patients with acute stroke could be a safe therapy for promoting neurovascular...” PMID 25304723 ↗ Oct 2014 |
| Modality | Cell therapy | “allogeneic mesenchymal stem cells (MSCs) from adipose tissue” PMID 25304723 ↗ Oct 2014 |
| Route | Intravenous | “It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.” NCT01678534 ↗ |